Tyler Stone Wealth Management Has $1.18 Million Holdings in Pfizer Inc. (NYSE:PFE)

Tyler Stone Wealth Management grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 42.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 44,469 shares of the biopharmaceutical company's stock after buying an additional 13,313 shares during the quarter. Tyler Stone Wealth Management's holdings in Pfizer were worth $1,180,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC bought a new stake in Pfizer during the fourth quarter worth approximately $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer in the fourth quarter worth approximately $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently commented on PFE shares. Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Bank of America restated a "neutral" rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Remove Ads

Insider Activity

In other news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Up 0.3 %

PFE stock traded up $0.07 during trading hours on Friday, hitting $25.08. The company's stock had a trading volume of 18,956,620 shares, compared to its average volume of 44,943,742. The stock has a 50 day moving average price of $26.09 and a two-hundred day moving average price of $26.97. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a market capitalization of $142.21 billion, a PE ratio of 17.78, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same period in the prior year, the company posted $0.10 earnings per share. Pfizer's revenue for the quarter was up 24.7% on a year-over-year basis. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.